Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
ORGANIZATION
Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
An independent study group of policy veterans, known as Kusuri Mirai Juku, issued a proposal on Japan’s pharmaceutical policy measures on June 12, opposing the expansion of post-launch price adjustments based on cost-effectiveness analyses. The proposal provides the group’s assessment…
To read the full story
Related Article
- Think Tank Advocates Drug Price Hikes above Existing Levels to Reflect Inflation
September 25, 2026
- Think Tank Opposes Cap on Social Security Burden Ratio, Urges Pause in Off-Year Price Cuts
June 22, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- Policy Veterans’ Group Calls for Value-Based Pricing for Regenerative Medicine
November 14, 2025
- Policy Veterans’ Group Calls for Inflation-Linked Drug Pricing in FY2026 Reform
October 1, 2025
- Policy Veterans’ Group Urges Japan to More than Double Minimum Drug Prices
February 21, 2025
- Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics
October 3, 2024
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
May 10, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
- Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
- Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
- Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
- Study Group Launched by Drug Policy Veterans Pushes 6% Adjustment Rate
December 6, 2021
ORGANIZATION
- Rethink Labor Cost Calculations in Drug Pricing: Pharma Labor Group
November 5, 2026
- Medipal’s Choufuku Takes Over as JPWA Vice Chair
November 4, 2026
- Enhertu, Dupixent Win 2026 International Prix Galien Biotechnology Award
November 2, 2026
- Pharma Trade Groups Flag Potential Leak of 30,000 Email Addresses
November 2, 2026
- Pharma Urges Drug Security, Demands 8.5% Price Hike: LDP Hearing
October 30, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…